Key facts
- Curlim’s last known valuation is $7.2M (Jan 2025).
- It has raised $14.1M.
- Notable investors include AQUITI Gestion, Avrul, Nouvelle Aquitaine Co-Investissement.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Curlim
- ·The full record, as it builds
Funding rounds
No funding rounds for Curlim are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Curlim
Operator of a drug technology company intended to treat peripheral neuropathies. The company's technology uses cellulose nanocrystals for enhanced penetration of curcumin into cells, the solubilization and protection of curcumin by beta-cyclodextrin, and a significant increase in curcumin's bloodstream lifespan, enabling clients to reduce the risk of peripheral neuropathies.
- Sector
- Healthcare
- HQ
- Limoges, France
- Founded
- 2024
- Employees
- 6
- Website
- curlim.eu/
- Ownership
- Privately Held (backing)
Curlim doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Curlim shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Curlim in its N-PORT filings yet. We sweep new filings monthly.